STOCK TITAN

Avita Medical (RCEL) Stock Price, News & Analysis

RCEL NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
52 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+63.6% close of August 7, 2026
1-year change
+306.8% closing prices, November 20, 2025 to November 20, 2026
1-month change
+13.2% closing prices, October 20, 2026 to November 20, 2026

Company Description

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) is a therapeutic acute wound care company in the surgical and medical instrument manufacturing industry. According to the company’s public disclosures, its technologies are designed to optimize wound healing and accelerate the time to patient recovery. AVITA Medical focuses on acute wound treatment, particularly thermal burn and trauma wounds, through a platform built around its RECELL System and complementary wound care products.

Core business and products

At the forefront of AVITA Medical’s platform is the RECELL System, which is approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. Company materials describe RECELL as a system that harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, used at the point-of-care. The RECELL System is intended to promote wound closure and recovery while reducing donor site burden compared with traditional split-thickness skin grafts.

In the United States, AVITA Medical also holds the rights to manufacture and the exclusive rights to market, sell, and distribute PermeaDerm, described as a biosynthetic wound matrix. In addition, the company holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical–branded collagen-based dermal matrix. Together with RECELL, these products form an integrated, multi-product acute wound care portfolio targeting burn, trauma, and related surgical settings.

Clinical evidence and role in acute wound care

AVITA Medical reports that global clinical and real-world data support the use of the RECELL System in acute wound treatment. A systematic review of peer-reviewed literature and registry analyses cited by the company describe outcomes such as reduced donor site size, faster healing, and reduced patient burden compared with traditional grafting approaches. Real-world registry data from the American Burn Association’s Burn Care Quality Platform, as referenced in company communications, highlight shorter hospital stays, higher rates of discharge to home, and favorable economic impact when RECELL is used for certain burn patients.

These findings are presented by AVITA Medical as evidence that RECELL can function as a standard of care in acute wound treatment across diverse wound types, patient populations, and care settings. The company also notes that clinical conference presentations and global analyses of thousands of patients have reinforced the clinical, operational, and economic value of the RECELL System.

Regulatory footprint and markets

AVITA Medical states that the RECELL System is approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. In international markets, the company reports that RECELL is approved to promote skin healing in a range of applications, including thermal burn and trauma wounds, with regulatory clearances in Europe and, excluding RECELL GO, in Australia and Japan. These clearances support the company’s ability to make RECELL technology available to clinicians treating acute wounds in multiple regions.

The company has also highlighted regulatory milestones such as CE Mark approval for RECELL GO under the European Union Medical Device Regulation, enabling commercialization in European markets beginning with Germany, Italy, and the United Kingdom. In Australia, AVITA Medical has reported that the Medical Services Advisory Committee recommended amendments to the Medicare Benefits Schedule to include autologous skin cell suspension prepared with RECELL for the treatment of severe acute burn wounds in adults and children, recognizing RECELL as safe and effective with benefits in healing, donor site sparing, and reduced hospital stays.

Business focus and capital structure

AVITA Medical describes its business focus as delivering transformative acute wound care solutions and building an integrated wound care platform. Company updates emphasize efforts to strengthen its capital structure, manage operating expenses, and align spending with growth priorities. AVITA Medical has entered into credit agreements and amendments with healthcare-focused lenders, including a senior secured credit facility with Perceptive Credit Holdings V, LP and prior credit arrangements with affiliates of OrbiMed Advisors, LLC, as disclosed in its Form 8-K filings.

The company has also raised capital through equity placements, including the issuance of CHESS Depositary Interests to Australian institutional and professional investors, as reported in its SEC filings. These financing activities are described as supporting the growth of its acute wound care portfolio and providing additional financial flexibility.

Corporate governance and listing

AVITA Medical is domiciled in the United States and has its primary listing there, with its common stock trading on NASDAQ under the symbol RCEL and on the Australian Securities Exchange under the symbol AVH. The company has reported changes in its board and executive leadership through Form 8-K filings, including the appointment of an interim chief executive officer and the addition of independent directors with experience in medical technology, healthcare systems, and surgery. These governance updates are presented as steps to support the company’s long-term strategy in acute wound care.

Position within the medical device landscape

Within the broader manufacturing sector, AVITA Medical operates in surgical and medical instrument manufacturing with a specific focus on therapeutic acute wound care. Its disclosures emphasize a platform centered on autologous skin cell suspension and dermal matrices for burn and trauma care, supported by clinical evidence and regulatory approvals. Investors and clinicians reviewing AVITA Medical typically focus on the adoption and utilization of the RECELL System, the performance of PermeaDerm and Cohealyx in the company’s portfolio, regulatory developments in key markets, and the company’s ability to manage its capital structure and operating expenses.

Stock Performance

$15.31
-1.98%
-0.31
After hoursChange vs the $15.62 closeLast updated: at
+306.8%
Performance 1 year
$471.2M

Avita Medical (RCEL) closed at $15.62 on November 20, 2026. Over the past 12 months, the price has gained 306.8%.

See what a $1,000 investment in RCEL would be worth today

Average down calculator for RCEL

RCEL Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Avita Medical has 10 recent news articles, with the latest published on . Of the recent coverage, 7 articles coincided with positive price movement and 3 with negative movement. Key topics include conferences, earnings, earnings date. View all RCEL news →

Financial Highlights

Avita Medical generated $71.6M in revenue in FY2025, retaining a 82.1% gross margin, operating income reached -$42.5M (-59.4% operating margin), and net income was -$48.6M, reflecting a -67.8% net profit margin. Diluted earnings per share stood at -$1.74. The company generated -$31.2M in operating cash flow. The current ratio was 0.57, measuring current assets divided by current liabilities.

$71.6M
Revenue (FY2025)
-$48.6M
Net Income (FY2025)
-$31.2M
Operating Cash Flow

Upcoming Events

YEAR
2027
2027 Regulatory

CMS 2027 payment update

Proposed 2027 CMS Medicare payment updates could add national physician and higher facility rates for RECELL if finalized.
JAN
01
January 1, 2027 Regulatory

Medicare valuation effective

National Medicare physician valuations and new bundled billing codes for RECELL procedures take effect Jan 1, 2027; impacts payments.
JAN
01
January 1, 2027 Regulatory

RECELL payment values

CMS finalized RECELL physician payment values and simplified billing codes, effective Jan 1, 2027; affects reimbursement and billing.

Avita Medical has 3 upcoming scheduled events. The next event, "CMS 2027 payment update", is expected in 2027. Investors can track these dates to stay informed about potential catalysts that may affect the RCEL stock price.

Short Interest History

Last 12 Months

Short interest in Avita Medical (RCEL) currently stands at 2.8 million shares, down 1.0% from the previous reporting period, representing 9.1% of the float.

Days to Cover History

Last 12 Months

Days to cover for Avita Medical (RCEL) currently stands at 6.1 days, down 19.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 56.2%. Across the settlements charted above, it has ranged from 2.5 to 20.7 days.

RCEL Company Profile & Sector Positioning

Avita Medical (RCEL) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing RCEL often look at related companies in the same sector, including Anteris Technologies Global Corp. (AVR), Cerus Corp (CERS), Sight Sciences, Inc. (SGHT), Tactile Systems Technology, Inc. (TCMD), and Senseonics Holdings, Inc. (SENS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate RCEL's relative position within its industry.

Frequently Asked Questions

The current stock price of Avita Medical (RCEL) is $15.31 in after-hours trading as of November 20, 2026.

The market cap of Avita Medical (RCEL) is approximately $471.2M. Learn more about what market capitalization means .

The FY2025 revenue of Avita Medical (RCEL) is $71.6M, from its most recent completed fiscal year.

The FY2025 net income of Avita Medical (RCEL) is -$48.6M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Avita Medical (RCEL) is -$1.74 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Avita Medical (RCEL) is -$31.2M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Avita Medical (RCEL) is -67.8% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Avita Medical (RCEL) is -59.4% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Avita Medical (RCEL) is 82.1% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Avita Medical (RCEL), current assets divided by current liabilities, was 0.57 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Avita Medical (RCEL) is $58.8M for FY2025, its most recent completed fiscal year.

The operating income of Avita Medical (RCEL) is -$42.5M for FY2025, its most recent completed fiscal year. Learn about operating income.

AVITA Medical, Inc. is a therapeutic acute wound care company in the surgical and medical instrument manufacturing sector. It focuses on technologies designed to optimize wound healing and accelerate patient recovery, particularly for thermal burn and trauma wounds.

The RECELL System is AVITA Medical’s core technology, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. The company describes RECELL as harnessing a patient’s own skin to create Spray-On Skin Cells at the point-of-care to support wound closure and recovery.

In the United States, AVITA Medical holds the rights to manufacture and exclusive rights to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical–branded collagen-based dermal matrix.

AVITA Medical reports that in international markets the RECELL System is approved to promote skin healing in a range of applications, including thermal burn and trauma wounds, with regulatory clearances in Europe and, excluding RECELL GO, in Australia and Japan.

The company cites global peer-reviewed evidence and real-world registry data showing that RECELL can reduce donor site size and burden, achieve rapid and reliable wound closure, and contribute to faster healing and reduced patient burden. Registry analyses also report shorter hospital stays and favorable economic outcomes in certain burn populations.

AVITA Medical’s common stock trades on NASDAQ under the ticker symbol RCEL. The company is also listed on the Australian Securities Exchange under the symbol AVH.

AVITA Medical has reported CE Mark approval for RECELL GO under the EU Medical Device Regulation, enabling commercialization in Europe, and has highlighted that Australia’s Medical Services Advisory Committee recommended Medicare Benefits Schedule changes to include autologous skin cell suspension prepared with RECELL for severe acute burns.

According to its SEC filings, AVITA Medical has entered into senior secured credit facilities, including a loan facility with Perceptive Credit Holdings V, LP, and has amended prior credit agreements with affiliates of OrbiMed Advisors, LLC. It has also raised equity capital through placements of CHESS Depositary Interests to institutional and professional investors in Australia.